Glp

Newest Glp Information

GLP-1 vs GLP-2 vs GLP-3 Explained: The Naming Confusion, the Real Science, and What You're Actually Buying

In the research peptide community, "GLP-1," "GLP-2," and "GLP-3" are informal shorthand nicknames used by some suppliers to relabel semaglutide, tirzepatide, and retatrutide - not actual distinct receptor classifications. The real science is that all three compounds work through the GLP-1 receptor system, with tirzepatide adding GIP receptor activity and retatrutide adding both GIP and glucagon receptor activity, making them a dual agonist and triple agonist respectively. If you have seen product names like GLP1-SEMA, GLP2-TIRZ, or GLP3-RT on a supplier site, this guide decodes what those labels actually mean and explains what the underlying science actually says.

Glp 16 min read

Switching from Tirzepatide to Retatrutide: What to Expect and Why It Might Be Worth It

Retatrutide adds glucagon receptor agonism to the dual GIP/GLP-1 mechanism of tirzepatide, which increases resting energy expenditure and accelerates fat oxidation beyond what appetite suppression alone achieves. Phase 2 trial data shows retatrutide producing substantially higher weight loss than tirzepatide's established clinical benchmarks, making it a logical consideration for people who have plateaued on tirzepatide or want a higher ceiling on metabolic outcomes. Retatrutide remains investigational as of the time of writing - it is not yet FDA-approved - so access comes through research peptide channels rather than pharmacy dispensing, and no formal switching protocol from tirzepatide has been clinically established.

Glp 13 min read

Switching from Semaglutide to Retatrutide: What to Expect and Whether It's Worth It

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, producing greater weight loss in Phase 2 trials than semaglutide's single GLP-1 mechanism, primarily because the glucagon component directly increases energy expenditure rather than relying on appetite suppression alone. People switching from semaglutide typically report stronger satiety, faster fat loss once retatrutide is fully titrated, and a handful of new side effects that semaglutide does not produce - including a resting heart rate increase and skin sensitivity. The main considerations before switching are that retatrutide is not yet FDA-approved, carries a higher GI burden than semaglutide at therapeutic doses, and has limited long-term human safety data - all factors worth discussing with a qualified prescriber before making any change.

Glp 12 min read

Switching from Semaglutide to Tirzepatide: What to Know Before You Make the Change

Tirzepatide activates two hormone receptors instead of one, which is why its clinical trials show meaningfully greater weight loss than semaglutide - 16.5 to 22.4 percent of body weight versus roughly 15 percent for semaglutide at approved doses. For people who have plateaued on semaglutide, want stronger metabolic effects, or simply want to understand whether switching makes sense, tirzepatide represents a genuinely different pharmacological approach rather than just a newer version of the same thing. The transition itself is straightforward - there is no washout period, and you start tirzepatide at the lowest dose the week after your last semaglutide injection - but there are important things to understand about the adjustment period before you make the move.

Glp 15 min read

Switching from Compounded GLP-1s to Research Peptides: Save Hundreds a Month Without Changing Your Dose

Compounded GLP-1 medications like semaglutide and tirzepatide and their research-grade peptide equivalents are chemically the same compound - the only difference is the form factor and the source. Compounded versions arrive pre-mixed in liquid form from a pharmacy; research peptides arrive as lyophilized (freeze-dried) powder that you mix yourself with bacteriostatic water. The dose, the titration schedule, and the weekly injection routine stay exactly the same after the switch. Most people making this transition reduce their monthly cost by $300 to $800 or more, with no change to their protocol or their results.

Glp 15 min read

GLP Peptide Comparison: Semaglutide, Tirzepatide, Retatrutide, and Beyond

The major GLP-based peptides - semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, and mazdutide - each activate different combinations of three receptors: GLP-1, GIP, and the glucagon receptor. That receptor profile is what determines how each compound performs on appetite suppression, weight loss, metabolic markers, and side-effect tolerability. Tirzepatide leads on food-noise elimination and appetite suppression at standard doses; retatrutide leads on raw weight-loss magnitude at higher doses; semaglutide is the most established with the deepest long-term safety data. Orforglipron is the only oral small-molecule option in this class currently approaching regulatory approval. Understanding these distinctions is what makes the difference between picking a compound that fits your goals and picking one that does not.

Glp 19 min read

dont Spend six hours researching every peptide.

About MyPeptidePal

MyPeptidePal is the world's largest peptide knowledge base and your personal AI peptide expert in one. Trained on every published study and over 10,000 protocols, it gets smarter every day, learning from new research and a community actively running and tracking their own. Build a personalized protocol in 60 seconds, get dosing math you can trust, find vetted suppliers, set auto-pilot reminders, and get straight answers on peptides, health, fitness, and longevity, all in one place. Try for FREE Here, no credit card required.